Human Leucocyte Antigen-Associated Graft Disease: Molecular Mechanisms, Therapeutic Strategies, and Pharmaceutical-Commercial Implications

Human leucocyte antigen (HLA) polymorphism is a major determinant of alloimmune recognition following transplantation, influencing graft-versus-host disease (GVHD) in allogeneic haematopoietic stem-cell transplantation (HSCT) and antibody-mediated rejection (AMR) in solid-organ transplantation. Although both involve alloimmune responses, their underlying mechanisms, tissue targets, diagnostic approaches, and therapeutic strategies differ substantially. Advances in HLA assessment, including high-resolution allele typing, HLA-DP and HLA-DQ evaluation, epitope and eplet analysis, and donor-specific antibody (DSA) profiling, have expanded the understanding of immunological risk. Emerging technologies, such as donor-derived cell-free deoxyribonucleic acid (DNA), transcriptomic assays, digital pathology, immune repertoire sequencing, and pharmacogenomics, offer additional opportunities for personalised transplant monitoring, although their clinical utility requires further validation. Therapeutic advances have similarly expanded treatment options. Targeted agents, including ruxolitinib for steroid-refractory acute GVHD, and belumosudil and axatilimab for chronic GVHD, represent important developments in pathway-directed therapy. In AMR, antibody removal, B-cell depletion, plasma-cell targeting, complement inhibition, and costimulatory blockade address different components of humoral alloimmunity, although effective long-term management of chronic AMR remains challenging. The convergence of advanced HLA typing, molecular diagnostics, biomarker-guided monitoring, and targeted therapeutics offers significant opportunities for precision transplantation. Integrating these approaches into clinical practice and pharmaceutical development will require reproducible assays, robust clinical validation, and evidence that their implementation improves meaningful patient outcomes.

Authors

Publication Details

Published
2026-11-16
DOI
https://doi.org/10.62830/mmj3-04-4b
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Human Leucocyte Antigen-Associated Graft Disease: Molecular Mechanisms, Therapeutic Strategies, and Pharmaceutical-Commercial Implications

Sinthia Mondal
1 links
Hematopoietic Stem Cell Transplantation
article

Human Leucocyte Antigen-Associated Graft Disease: Molecular Mechanisms, Therapeutic Strategies, and Pharmaceutical-Commercial Implications

Sinthia Mondal
article en

Abstract

Human leucocyte antigen (HLA) polymorphism is a major determinant of alloimmune recognition following transplantation, influencing graft-versus-host disease (GVHD) in allogeneic haematopoietic stem-cell transplantation (HSCT) and antibody-mediated rejection (AMR) in solid-organ transplantation. Although both involve alloimmune responses, their underlying mechanisms, tissue targets, diagnostic approaches, and therapeutic strategies differ substantially. Advances in HLA assessment, including high-resolution allele typing, HLA-DP and HLA-DQ evaluation, epitope and eplet analysis, and donor-specific antibody (DSA) profiling, have expanded the understanding of immunological risk. Emerging technologies, such as donor-derived cell-free deoxyribonucleic acid (DNA), transcriptomic assays, digital pathology, immune repertoire sequencing, and pharmacogenomics, offer additional opportunities for personalised transplant monitoring, although their clinical utility requires further validation. Therapeutic advances have similarly expanded treatment options. Targeted agents, including ruxolitinib for steroid-refractory acute GVHD, and belumosudil and axatilimab for chronic GVHD, represent important developments in pathway-directed therapy. In AMR, antibody removal, B-cell depletion, plasma-cell targeting, complement inhibition, and costimulatory blockade address different components of humoral alloimmunity, although effective long-term management of chronic AMR remains challenging. The convergence of advanced HLA typing, molecular diagnostics, biomarker-guided monitoring, and targeted therapeutics offers significant opportunities for precision transplantation. Integrating these approaches into clinical practice and pharmaceutical development will require reproducible assays, robust clinical validation, and evidence that their implementation improves meaningful patient outcomes.

Vol. III(04)
Good health and well-being
Hematopoietic Stem Cell Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon